Bell & Brown Wealth Advisors LLC Invests $2.46 Million in Bristol Myers Squibb Company $BMY

Key Points

• Bell & Brown Wealth Advisors acquired 42,598 Bristol Myers Squibb shares during the second quarter, investing approximately $2.46 million. Institutional investors and hedge funds collectively own 76.41% of BMY.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $66.06; individual targets range from $59 to $70.
• Bristol Myers Squibb reported quarterly EPS of $2.04, surpassing the $1.60 consensus, while revenue rose 5.7% year over year to $12.97 billion. The company also pays a quarterly dividend of $0.63 per share, representing a 3.7% annualized yield.

Bell & Brown Wealth Advisors LLC acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 42,598 shares of the biopharmaceutical company's stock, valued at approximately $2,455,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in BMY. Swiss RE Ltd. purchased a new position in shares of Bristol Myers Squibb during the 4th quarter worth $25,000. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb during the second quarter worth about $25,000. Physician Wealth Advisors Inc. grew its position in Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 202 shares during the last quarter. Bayban purchased a new position in Bristol Myers Squibb in the 4th quarter valued at $31,000. Finally, EQ Wealth Advisors LLC acquired a new position in Bristol Myers Squibb in the 4th quarter valued at $32,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Wells Fargo & Company set a $65.00 price objective on shares of Bristol Myers Squibb and gave the stock an "equal weight" rating in a research report on Friday, July 31st. Raymond James Financial assumed coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a "strong-buy" rating for the company. Cantor Fitzgerald reissued a "neutral" rating and issued a $59.00 price objective (up from $54.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Jefferies Financial Group downgraded shares of Bristol Myers Squibb from a "buy" rating to a "hold" rating in a research note on Wednesday, August 5th. Finally, Truist Financial reaffirmed a "buy" rating and set a $70.00 price target (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $66.06.

Bristol Myers Squibb Stock Performance

Bristol Myers Squibb stock opened at $67.59 on Thursday. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64. The stock has a 50 day moving average of $60.18 and a 200-day moving average of $59.24. The stock has a market cap of $138.06 billion, a P/E ratio of 14.89, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company's revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period last year, the firm earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, analysts expect that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 3.7%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb's payout ratio is presently 55.51%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source